醫藥股普遍逆市造好 信達生物漲逾9% 惟國藥及康希諾跌4%-6.6%
恆指今早高開29點,回升至26,436無以為繼,掉頭曾倒跌261點,低見26,127喘定,現造26,259,續吐130點或0.5%;國指跌0.3%,報10,411。
不過,醫藥相關股今早普遍逆市造好,上周五指宮頸癌聯合療法二期臨床研究完成首例患者給藥的信達生物(01801.HK)升破50天線(58.21元),最高見61.9元,現造61.4元,回升9.2%。
藍籌石藥(01093.HK)及中生製藥(01177.HK)逆市連續第二天反彈,兩者股價均重越10天線(7.52元及6.81元),最高見7.61元及7.08元,現造7.57元及7.01元,續彈3.8%及3.7%。同為藍籌藥明生物(02269.HK)低見77.7元獲承接,掉頭高見81.25元,現造80.9元,回升3.5%。藥明康德(02359.HK)高見132.6元,現造132.2元,續升3.1%。
微創醫療(00853.HK)續升5.1%報39.25元;君實生物(01877.HK)續升2.3%報45.25元。復星醫藥(02196.HK)反覆三連升,報36.6元,反覆續升0.8%。聯邦制藥(03933.HK)重越10天線(5.78元),最高見5.88元,現造5.81元,回升2.5%。威高股份(01066.HK)反覆重越10天線(14.45元),現造14.62元,反覆續升1.8%。
相反,國藥(01099.HK)股價失守50天及百天線(18.29元及18.4元),最低見18.12元,現造18.16元,續跌4%。早前遭基金減持的康希諾生物(06185.HK)三連跌,最低見152.5元,現造157元,續跌6.6%。
據《中國證券報》報道,內地第四批藥品國家集採拉開序幕,部分公司因競品納指集採,火速公告預警提示降價風險。報道引述一位藥企負責人表示,較為關注高端仿製藥降價幅度,這對公司未來產品佈局至關重要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.